Back to search results

Observational Study of Acute Normovolemic Hemodilution and Kidney Injury

This study is looking at how a blood conservation technique called Acute Normovolemic Hemodilution (ANH) affects kidney injury during heart surgery. ANH involves taking out some of your blood before surgery and giving it back afterward to reduce bleeding and the need for blood transfusions. Researchers will compare patients who receive ANH to those who don't. The study will measure specific markers in your urine, NGAL and KIM-1, 24 hours after surgery to see if ANH helps prevent acute kidney injury. You may be able to join if you are between 18 and 70 years old, weigh over 70kg, have a hemoglobin level above 12 g/dL, and are having elective coronary artery bypass graft surgery. The current recruitment status is unclear.

Study design
This is an observational study with 100 participants. Patients will be randomly divided into two groups: one receiving ANH and the other not.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Urinary biomarkers will be measured 24 hours after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05349292

Acute Normovolemic Hemodilution on Urine Neutrophil Gelatinase-associated Lipocalin Levels

Recruiting
Not specifiedAges 18–70Observational
University of Maryland, Baltimore
~100 participants
Updated 2026-05-01 on ClinicalTrials.gov
What's tested:ANH

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Urinary Biomarkers NGAL and KIM-1
Measured over 24 hours

Conditions

Acute Kidney Injury

Explore related trials

Coronary Artery Disease

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Patrick Odonkor, MD · PRINCIPAL_INVESTIGATOR · University of Maryland, Baltimore

Who to contact

Patrick Odonkor, MD
[email protected]
4103286120
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Elective Coronary Artery Bypass Graft Surgery
Age 18-70 years
Anticipated Cardiopulmonary Bypass Duration less than 2 hours
Weight greater than 70kg
Hemoglobin greater than 12 g/dL

Exclusion

Emergency and redo cardiac surgery
Renal insufficiency with serum creatinine greater than 1.25 mg/dL and/ or estimated GFR less than 60 mL/min/1.73 m2
Heart Failure with EF \<40%
Hepatic disease
Pulmonary Disease, including pulmonary hypertension
Inherited or Acquired Bleeding Disease

What this trial measures

  • Urinary Biomarkers NGAL and KIM-124 hours

    Urinary levels of NGAL and KIM-1 biomarkers during the first 24 hours after CABG surgery